Ocular Therapeutix (OCUL) Cost of Revenue (2016 - 2025)
Historic Cost of Revenue for Ocular Therapeutix (OCUL) over the last 13 years, with Q4 2025 value amounting to $13.0 million.
- Ocular Therapeutix's Cost of Revenue rose 1952.95% to $13.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $53.9 million, marking a year-over-year increase of 2965.14%. This contributed to the annual value of $53.9 million for FY2025, which is 2965.14% up from last year.
- According to the latest figures from Q4 2025, Ocular Therapeutix's Cost of Revenue is $13.0 million, which was up 1952.95% from $13.1 million recorded in Q3 2025.
- In the past 5 years, Ocular Therapeutix's Cost of Revenue registered a high of $14.1 million during Q1 2025, and its lowest value of $8.1 million during Q1 2021.
- In the last 5 years, Ocular Therapeutix's Cost of Revenue had a median value of $10.2 million in 2022 and averaged $10.6 million.
- As far as peak fluctuations go, Ocular Therapeutix's Cost of Revenue skyrocketed by 4687.12% in 2021, and later tumbled by 1221.99% in 2023.
- Quarter analysis of 5 years shows Ocular Therapeutix's Cost of Revenue stood at $9.1 million in 2021, then grew by 15.28% to $10.5 million in 2022, then fell by 12.22% to $9.2 million in 2023, then grew by 17.25% to $10.8 million in 2024, then increased by 19.53% to $13.0 million in 2025.
- Its last three reported values are $13.0 million in Q4 2025, $13.1 million for Q3 2025, and $13.7 million during Q2 2025.